References
Neunert C, Terrell DR, Arnold DM et al (2019) American Society of Hematology 2019 guidelines for immune thrombocytopenia [published correction appears in Blood Adv. 2020 Jan 28;4(2):252]. Blood Adv 3(23):3829–3866
Ong SY, Tan CW, Ramya V, Malik AA, Lee XH, Hwang JCC, Yang Y, Ng HJ, Lee LH (2021) Risk factors and predictors of treatment responses and complications in immune thrombocytopenia. Ann Hematol. https://doi.org/10.1007/s00277-021-04424-z
Mishra K, Malhotra P, Jandial A, Kumar LD, Varma N, Dhiman RK, Yanamandra U et al (2017) Bleeding risk assessment by sonoclot in severe immune thrombocytopenia. Blood 130(Suppl 1):2320
Mishra K, Jandial A, Sandal R, Porchezhian P, Charan S, Lad D et al Poor platelet function on sonoclot signature is associated with high incidence of bleeding in severe immune thrombocytopenia. Blood 132(Suppl 1):4491. https://doi.org/10.1182/blood-2018-99-117086
Mishra K, Kumar S, Jandial A, Sahu KK, Sandal R, Ahuja A et al (2020 (accepted) Real-world experience of rituximab in immune thrombocytopenia. Indian J Hematol Blood Transfus 10.1007/s12288-020-01351-3
Mishra K, Pramanik S, Jandial A, Sahu KK, Sandal R, Ahuja A et al (2020) Real-world experience of eltrombopag in immune thrombocytopenia. Am J Blood Res. 10(5):240–251
Sahu KK, Varma SC (2015) Cortical vein thrombosis in a case of idiopathic thrombocytopenic purpura. Platelets. 26(4):374–5
Wong RSM, Saleh MN, Khelif A, Salama A, Por-tella MSO, Burgess P, Bussel JB (2017) Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood 130:2527–2536
Kim YK, Lee SS, Jeong SH, Ahn JS, Yang DH, Lee JJ, Kim HJ (2015) Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia. Blood Res 50:19–25
Author information
Authors and Affiliations
Contributions
All authors have seen the manuscript and agree to the content and data. All the authors played a significant role in the paper
Corresponding author
Ethics declarations
Ethical approval
The article does not contain the participation of any human being and animal.
Conflict of interest
The authors declare no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Mishra, K., Sahu, K.K. Re: Risk factors and predictors of treatment responses and complications in immune thrombocytopenia. Ann Hematol 101, 447–448 (2022). https://doi.org/10.1007/s00277-021-04476-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-021-04476-1